Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference
TARRYTOWN, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference virtually on Wednesday, June 11, 2025 at 10:30 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors' section and the "Events and Presentations" tab, or by using the following link:
https://ir.prestigebrands.com/events-presentations/events
For those unable to participate during the live webcast, a replay option will be available on the Company's website following the event.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company's diverse portfolio of brands include Monistat® and Summer's Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux's Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
CONTACT: Investor Relations Contact Phil Terpolilli, CFA, 914-524-6819 irinquiries@prestigebrands.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Johnson Fistel Continues Investigation on Behalf of SentinelOne, Inc. Shareholders
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating claims on behalf of SentinelOne, Inc. (NYSE: S) against certain of its officers and directors. If you are a current, long-term shareholder of SentinelOne, continuously holding shares since June 1, 2022, you may have standing to hold the company harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. You can click or copy and paste the link below in a browser to join this action: Previously, a class action complaint was filed against the company. The class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) SentinelOne lacked effective internal controls over accounting and financial reporting; (ii) as a result, SentinelOne's Annualized Recurring Revenue ("ARR") was overstated; and (iii) consequently, SentinelOne's guidance was overstated. About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, PLLP can help you recover your losses. For more information about the firm and its attorneys, please visit Achievements: In 2024, Johnson Fistel was honored to be ranked in the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. This recognition underscores our effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where we served as lead or co-lead counsel. This notable accomplishment marks the eighth occasion our firm has been recognized as a top plaintiffs' securities law firm in the United States, as determined by the total dollar value of final recoveries. Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Yahoo
an hour ago
- Yahoo
Global Uranium Corp. Announces LIFE Offering for up to C$1,500,000
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 10, 2025 (GLOBE NEWSWIRE) -- Global Uranium Corp. (CSE: GURN | FRA: Q3J) (the 'Company') is pleased to announce that it intends to complete a non-brokered private placement financing (the 'Offering') of a minimum of 1,666,666 units of the Company (each, a 'Unit') and a maximum of 10,000,000 Units, at a price of C$0.15 per Unit, for gross minimum proceeds of C$250,000 and gross maximum proceeds of C$1,500,000. Each Unit shall be comprised of one common share in the capital of the Company (each, a 'Share') and one Share purchase warrant ('Warrant'), with each Warrant entitling the holder to purchase one Share at a price of C$0.20 for a period of 24 months from Closing (as defined herein). Closing of the Offering is anticipated to occur on or about July 25, 2025 ('Closing'), subject to the satisfaction of certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. The net proceeds of the Offering are intended to be used for exploration activities, for general administrative expenditures, and for general working capital purposes. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions ('NI 45-106'), the securities issuable under the Offering will be offered for sale to purchasers resident in all of the provinces of Canada (except Quebec) pursuant to the listed issuer financing exemption under Part 5A.2 of NI 45-106 (the 'LIFE Exemption'). As such, the securities issued to subscribers will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an offering document dated June 10, 2025 related to the Offering that can be accessed under the Company's profile at and on the Company's website at This offering document contains additional detail regarding the Offering, including additional detail regarding the expected use of proceeds therefrom. Prospective investors in the Offering should read this offering document before making an investment decision. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any United States state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any available exemption from the registration requirements of the U.S. Securities Act and applicable United States state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. ABOUT GLOBAL URANIUM CORP. Global Uranium Corp. focuses on exploring and developing uranium assets primarily in North America. The Company currently holds key uranium projects: the Wing Lake Property in the Mudjatik Domain of Northern Saskatchewan, Canada; the Northwest Athabasca Joint Venture with Forum Energy Metals Corp. and NexGen Energy Ltd. in the Northwest Athabasca region of Saskatchewan, Canada; the Astro Uranium Project with Cosa Resources Corp in the eastern Athabasca Basin, Saskatchewan; and the Great Divide Basin District Projects, the Gas Hills District Projects, and the Copper Mountain District Projects in Wyoming, USA. ON BEHALF OF THE BOARD OF DIRECTORSUngad ChaddaCEO 587-330-0045info@ FORWARD-LOOKING STATEMENTS Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words 'could', 'intend', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. In particular, this press release contains forward-looking information relating to, among other things, the Offering, including the total anticipated proceeds, the expected use of proceeds, and the closing (including the proposed closing date) of the Offering. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information, including the assumption that the Company will close the Offering on the timeline anticipated, will raise the anticipated amount of gross proceeds from the Offering and will use the proceeds of the Offering as anticipated. Those assumptions and factors are based on information currently available to the Company. Although such statements are based on reasonable assumptions of the Company's management, there can be no assurance that any conclusions or forecasts will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include: the risk that the Offering does not close on the timeline expected, or at all; the risk that the Company raises less than the anticipated amount of gross proceeds from the Offering; the risk that the Company does not use the proceeds from the Offering as currently expected; risks inherent in the exploration and development of mineral deposits, including risks relating to receiving requisite permits and approvals, changes in project parameters or delays as plans continue to be redefined, that mineral exploration is inherently uncertain and that the results of mineral exploration may not be indicative of the actual geology or mineralization of a project; that mineral exploration may be unsuccessful or fail to achieve the results anticipated by the Company; operational risks; regulatory risks, including risks relating to the acquisition of the necessary licenses and permits; financing, capitalization and liquidity risks; title and environmental risks; and risks relating to the failure to receive all requisite regulatory approvals. The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein. The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this press release.Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
ColonBroom GLP-1 Booster Website Updated to Highlight Daily Supplement for Metabolic Health
New website update showcases natural GLP-1 support supplement designed to curb cravings, support metabolism, and promote healthy weight management SAN FRANCISCO, June 10, 2025 (GLOBE NEWSWIRE) -- ColonBroom, a U.S.-based wellness brand, has announced a new update to its official website to highlight the launch of ColonBroom GLP-1 Booster—a daily supplement formulated to support metabolic function, appetite regulation, and overall weight wellness. Now available across the United States, the product offers a natural, lifestyle-friendly solution backed by science-supported ingredients. According to the official product website ( ColonBroom GLP-1 Booster is designed to work alongside the body's internal systems by promoting satiety, curbing cravings, and supporting blood sugar balance. The formula targets key wellness goals like reducing excess visceral fat and helping users manage weight more effectively without relying on restrictive diets or intense routines. 'ColonBroom GLP-1 Booster reflects our mission to simplify wellness with natural tools that align with modern lifestyles,' said a company spokesperson. 'This formula is designed with purpose—combining evidence-backed ingredients for those seeking real metabolic support.' The formulation includes Berberine, Chromium Picolinate, 5-HTP, Saffron Extract, and Bupleurum Root Extract—ingredients selected for their known roles in supporting GLP-1 activity, blood sugar balance, mood regulation, and fat metabolism. ColonBroom confirms that all supplements are manufactured in facilities that adhere to rigorous quality and safety protocols. The brand offers a satisfaction guarantee for new customers and invites visitors to explore ingredient insights, customer FAQs, and personalized quiz recommendations directly on the website. About ColonBroom ColonBroom is a San Francisco-based wellness brand dedicated to creating clean, effective, and easy-to-use daily supplements. With a focus on transparency and science-backed simplicity, ColonBroom empowers adults to take proactive steps toward digestive and metabolic wellness. Product and Contact Information Brand: ColonBroomWebsite: hello@ (Order Support): 1-888-505-0855Mailing Address: 505 Montgomery Street, 10th & 11th Floors, San Francisco, California, 94111, USA Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. CONTACT: Email: hello@ Phone (Order Support): 1-888-505-0855Sign in to access your portfolio
